Johann Bauersachs

Nov 2, 2024 | jacc.org | Shingo Matsumoto |Pardeep S. Jhund |Alasdair Henderson |Johann Bauersachs

IntroductionKidney dysfunction often leads to reluctance to continue disease-modifying therapies in patients with heart failure (HF).

May 28, 2024 | academic.oup.com | Baylor Heart |John F |Johann Bauersachs |Milton Packer

Heart failure with reduced ejection fraction (HFrEF) entails a poor prognosis if not adequately treated.

Mar 21, 2024 | onlinelibrary.wiley.com | Johann Bauersachs |Alice Jackson |Karen Sliwa

Letter to the Editor Reply to ‘Breaking down peripartum cardiomyopathy: A learning adventure’ Johann Bauersachs,  Johann Bauersachs Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany Contributed equally as co-first authors. Search for more papers by this authorAlice M Jackson,  Alice M Jackson Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK Contributed equally as co-first authors.

Oct 12, 2023 | onlinelibrary.wiley.com | Alice Jackson |Johann Bauersachs |Mark C. Petrie |Cécile Laroche

Introduction Peripartum cardiomyopathy (PPCM), a type of de novo heart failure occurring around the time of delivery or in the following months, is generally characterized by a dilated cardiomyopathy phenotype, associated with adverse outcomes such as death, persistent left ventricular (LV) dysfunction and thromboembolic complications, but also with frequent LV recovery.1 Region appears to be an important determinant of outcomes; in the European Society of Cardiology (ESC) EURObservational...

Apr 5, 2023 | jacc.org | Stephen Greene |Johann Bauersachs |Jasper J. Brugts |Justin A. Ezekowitz

JACC Journals › JACC › Archives › Vol. 82 No. 6 AbstractDespite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapidly evolving evidence-base, as a number of recent clinical trials have demonstrated multiple therapies to be safe and efficacious in this high-risk population.